北京大成(广州) 律师事务所 关于湖南南新制药股份有限公司 2026 年第一次临时股东会的 大成 DENTONS 法律意见书 大成 is Dentons' Preferred Law Firm in China. guangzhou.dachenglaw.com 广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 14 层、15 层（510623） 14/F,15/F CTF Finance Centre No 6 Zhujiang East Road Tianhe District 510623, Guangzhou, China Tel:+8620-85277000 Fax:+8620-85277002 北京大成(广州)律师事务所 关于湖南南新制药股份有限公司 2026年第一次临时股东会法律意见书 致: 湖南南新制药股份有限公司 2026 年 1 月 26 日 , 公司董事会在第二届董事会第二十一次会议上审议通过 了《关于提请召开 2026 年第一次临时股东会的议案》，决定于 2026 年 2 月 11 日召开 2026年第一次临时股东会。 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中 ...

经公司第二届董事会提名委员会进行任职资格审查后，公司于2026年2月11日召开第二届董事会第二十 二次会议，审议通过了《关于聘任公司总经理的议案》，同意聘任陈健旭先生担任公司总经理，任期自 本次董事会审议通过之日起至第二届董事会任期届满之日止。 格隆汇2月11日丨南新制药(688189.SH)公布，公司董事会于近日收到张世喜先生提交的书面辞职报告， 张世喜先生因工作调整原因申请辞去公司总经理职务。根据《公司法》《公司章程》的有关规定，张世 喜先生的辞职报告自送达董事会之日起生效。辞职后，张世喜先生仍担任公司董事、董事长、董事会战 略委员会召集人职务。 ...

Group 1 - The core issue is that Nanjing Pharmaceutical is under investigation by the China Securities Regulatory Commission for violations in annual report disclosures, highlighting significant flaws in the company's financial compliance [1][4] - The company has faced repeated accounting errors, including improper handling of sales returns and insufficient conditions for revenue recognition, leading to restatements of financial data [1][4] - The investigation represents a critical examination of the company's integrity and governance, emphasizing the importance for affected investors to protect their rights within the legal framework [1][4] Group 2 - Nanjing Pharmaceutical has announced a projected annual revenue of 120 million to 150 million yuan for 2025, a decline of approximately 43% to 54% compared to the previous year's revenue of 263 million yuan [2][4] - The company anticipates a net loss of 120 million to 160 million yuan, although this represents a reduction from the previous year's loss of 357 million yuan, indicating ongoing challenges in achieving profitability [2][4] - Factors contributing to the performance decline include intensified competition in the pharmaceutical industry and reduced demand for core products due to a decrease in flu cases, alongside a cautious approach to asset and credit impairment losses [2][5]

二、回购股份的进展情况 证券代码：688189 证券简称：南新制药 公告编号：2026-007 湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,910,214股 | | 累计已回购股数占总股本比例 | 0.70% | | 累计已回购金额 | 16,138,029.08元 | | 实际回购价格区间 | 7.02元/股~8.92元/股 | 一、回购股份的基本情况 湖南南新制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第 二届董事会第十五次会议 ...

格隆汇2月2日丨南新制药（维权）(688189.SH)公布，截至2026年1月31日，公司通过上海证券交易所交 易系统以集中竞价交易方式累计回购公司股份1,910,214股，占公司总股本的比例为0.70%，回购成交的 最高价为8.92元/股，最低价为7.02元/股，支付的资金总额为人民币16,138,029.08元（不含印花税、交易 佣金等交易费用）。 ...

Summary of Key Points Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) has announced a share buyback program, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1: Share Buyback Details - The company has repurchased a total of 1,910,214 shares, which represents 0.70% of its total share capital [1] - The highest price paid for the repurchased shares was 8.92 CNY per share, while the lowest price was 7.02 CNY per share [1] - The total amount spent on the buyback was 16,138,029.08 CNY, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The company expects a significant decline in revenue for the year 2025, projecting an operating income between 120 million to 150 million yuan, a decrease of 113.28 million to 143.28 million yuan compared to the previous year, representing a year-on-year decline of 43.03% to 54.42% [3] - The company anticipates a net loss attributable to shareholders of the parent company ranging from -160 million to -120 million yuan, which is a reduction in loss of 196.90 million to 236.90 million yuan compared to the previous year, indicating a year-on-year decrease in loss of 55.17% to 66.38% [3] - The projected net loss attributable to shareholders after excluding non-recurring gains and losses is expected to be between -165 million to -125 million yuan, with a reduction in loss of 193.53 million to 233.53 million yuan compared to the previous year, reflecting a year-on-year decrease in loss of 53.98% to 65.14% [4] Group 2 - The company reported a total profit loss of -388.64 million yuan for the year 2024, with a net loss attributable to shareholders of the parent company at -356.90 million yuan [6] - The earnings per share for the year 2024 were reported at -1.3007 yuan [7] Group 3 - The decline in performance is attributed to intensified market competition due to domestic pharmaceutical industry procurement policies and the introduction of similar competing products, along with a decrease in flu cases in the first three quarters of 2025, leading to reduced operating income and gross margin [8] - The company has maintained a high level of R&D investment to sustain its core competitiveness while implementing cost control measures, resulting in a significant decrease in sales and management expenses compared to the previous year [8] - Future strategies include adjusting marketing strategies, accelerating R&D progress, launching new products, optimizing product sales structure, and enhancing cost management to achieve sustainable and high-quality development [8]

Core Viewpoint - Company South New Pharmaceutical (688189.SH) expects a significant decline in revenue and net profit for the year 2025, primarily due to intensified market competition and reduced demand in the domestic pharmaceutical industry [1][2] Financial Performance - The projected revenue for 2025 is estimated to be between 120 million to 150 million yuan, representing a decrease of 113 million to 143 million yuan compared to the previous year, which is a year-on-year decline of 43.03% to 54.42% [1] - The expected net profit attributable to the parent company is projected to be a loss of 160 million to 120 million yuan, which is a reduction of 197 million to 237 million yuan compared to the previous year, reflecting a year-on-year decrease in losses of 55.17% to 66.38% [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to be a loss of 165 million to 125 million yuan, with a reduction in losses of 194 million to 234 million yuan compared to the previous year, indicating a year-on-year decrease in losses of 53.98% to 65.14% [1] Operational Factors - The decline in performance is attributed to intensified competition in the market due to domestic pharmaceutical procurement policies and the introduction of similar competing products [2] - The company has maintained a high level of R&D investment to sustain its core competitiveness despite the losses incurred [2] - Cost control measures have been implemented, resulting in a significant reduction in sales and management expenses compared to the previous year [2]

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) expects a significant decline in revenue and net profit for the fiscal year 2025, indicating ongoing financial challenges for the company [1] Financial Performance Summary - The company projects an annual revenue of between 120 million to 150 million yuan for 2025, which represents a decrease of 113.2848 million to 143.2848 million yuan compared to the previous year, translating to a year-on-year decline of 43.03% to 54.42% [1] - After excluding non-core business income and income lacking commercial substance, the expected revenue is between 119.9 million to 149.9 million yuan [1] - The anticipated net profit attributable to the parent company is expected to be a loss of between 160 million to 120 million yuan, which is a reduction in loss of 196.9036 million to 236.9036 million yuan compared to the previous year, reflecting a year-on-year decrease in loss of 55.17% to 66.38% [1] - The projected net profit attributable to the parent company, after excluding non-recurring gains and losses, is expected to be a loss of between 165 million to 125 million yuan, with a reduction in loss of 193.5310 million to 233.5310 million yuan compared to the previous year, indicating a year-on-year decrease in loss of 53.98% to 65.14% [1]

预计2025年年度归属于母公司所有者扣除非经常性损益后的净利润为-1.65亿元到-1.25亿元。与上年同 期相比，亏损减少1.94亿元到亏损减少2.34亿元，同比亏损减少53.98%到亏损减少65.14%。 本期业绩变化的主要原因：报告期内，公司生产经营活动正常。受国内医药行业集中采购等政策深入推 进、同类竞品不断上市等因素影响，导致市场竞争加剧，加之2025 年前三季度国内流感较少，导致公 司营业收入和毛利率均有所下降。报告期内，公司根据《企业会计准则》及公司会计政策等相关规定， 基于谨慎性原则，对各类资产计提资产减值损失及信用减值损失等。报告期内，为持续保持公司的核心 竞争力，公司仍保持较高强度的研发投入。基于以上因素，公司经营业绩发生亏损，但亏损幅度较上年 大幅减少。报告期内，公司持续推进各项降本增效措施，严格控制费用成本支出，全年实现销售费用、 管理费用等均较上年同期明显下降。 格隆汇1月30日丨南新制药(688189.SH)公布，经公司财务部门初步测算，预计2025年年度实现营业收入 1.2亿元到1.5亿元，与上年同期相比，将减少1.13亿元到1.43亿元，同比减少43.03%到54.42%；扣除与 ...